ArticleThe World Allergy Organization journal2026
Evaluation of drug causality in SJS/TEN: The role of the lymphocyte transformation test and conventional/modified IFN-γ ELISpot assays.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are life-threatening hypersensitivity reactions often triggered by specific drugs. Accurate detection of drug culprits is critical for patient management and prevention of similar conditions. This study evaluates and compares the diagnostic performance of the Lymphocyte Transformation Test (LTT), Conventional IFN-γ ELISpot, and Modified IFN-γ ELISpot assays (anti-CD3/CD28 and IL-2) in detecting drug-induced immune responses in SJS/TEN patients. Methods: The study involved 20 SJS/TEN patients who were diagnosed based on clinical features, causality assessment using the Naranjo algorithm, and SCORTEN scoring for severity. Blood samples were collected to isolate peripheral blood mononuclear cells (PBMCs), which were subjected to LTT and IFN-γ ELISpot assays that was assessed by conventional and modified assays, the latter involving T-cell pre-activation using anti-CD3/CD28 and IL-2. Drugs tested included carbamazepine, ciprofloxacin, phenytoin, sulphamethoxazole, clozapine, and gatifloxacin. Diagnostic parameters, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were calculated. The influence of systemic corticosteroid use on assay performance was also evaluated. Results: The Modified IFN-γ ELISpot assay demonstrated significantly higher sensitivity (80%) and NPV (88.2%) compared to the LTT (sensitivity: 30%, NPV: 68.2%) and Conventional IFN-γ ELISpot assay (sensitivity: 20%, NPV: 65.2%). All assays exhibited high specificity (100%) and PPV (100%). Among the 20 SJS/TEN patients, 7 (35%) were receiving systemic corticosteroids at the time of testing. Patients receiving systemic corticosteroids showed no significant differences in the 3 assays. Culprit drugs such as carbamazepine and ciprofloxacin elicited stronger immune responses compared to irrelevant drugs, highlighting assay specificity. Conclusions: The Modified IFN-γ ELISpot assay outperformed the LTT and Conventional IFN-γ ELISpot in detecting drug-induced immune responses in SJS/TEN patients, particularly for high-risk drugs such as carbamazepine and sulphamethoxazole. Its superior sensitivity and reliability suggest it its role in identifying the culprit drugs in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.